241 related articles for article (PubMed ID: 16155368)
41. Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects.
Beilfuss J; Berg V; Sneve M; Jorde R; Kamycheva E
Cytokine; 2012 Dec; 60(3):870-4. PubMed ID: 22925537
[TBL] [Abstract][Full Text] [Related]
42. Circulating TNF-alpha and leptin levels in offspring of NIDDM patients do not correlate to individual insulin sensitivity.
Kellerer M; Rett K; Renn W; Groop L; Häring HU
Horm Metab Res; 1996 Dec; 28(12):737-43. PubMed ID: 9013754
[TBL] [Abstract][Full Text] [Related]
43. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation.
Zhou MS; Schulman IH; Raij L
J Hypertens; 2010 Mar; 28(3):527-35. PubMed ID: 19898250
[TBL] [Abstract][Full Text] [Related]
44. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
[TBL] [Abstract][Full Text] [Related]
45. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.
Monk JP; Phillips G; Waite R; Kuhn J; Schaaf LJ; Otterson GA; Guttridge D; Rhoades C; Shah M; Criswell T; Caligiuri MA; Villalona-Calero MA
J Clin Oncol; 2006 Apr; 24(12):1852-9. PubMed ID: 16622259
[TBL] [Abstract][Full Text] [Related]
46. [Effect of metformin on the expression of tumor necrosis factor-α, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients].
Andrews M; Soto N; Arredondo M
Rev Med Chil; 2012 Nov; 140(11):1377-82. PubMed ID: 23677182
[TBL] [Abstract][Full Text] [Related]
47. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome.
Lo J; Bernstein LE; Canavan B; Torriani M; Jackson MB; Ahima RS; Grinspoon SK
Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E102-9. PubMed ID: 17374698
[TBL] [Abstract][Full Text] [Related]
48. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure.
Fichtlscherer S; Rössig L; Breuer S; Vasa M; Dimmeler S; Zeiher AM
Circulation; 2001 Dec; 104(25):3023-5. PubMed ID: 11748093
[TBL] [Abstract][Full Text] [Related]
49. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome.
Stanley TL; Zanni MV; Johnsen S; Rasheed S; Makimura H; Lee H; Khor VK; Ahima RS; Grinspoon SK
J Clin Endocrinol Metab; 2011 Jan; 96(1):E146-50. PubMed ID: 21047923
[TBL] [Abstract][Full Text] [Related]
50. Effect of etanercept on insulin sensitivity in nine patients with psoriasis.
Marra M; Campanati A; Testa R; Sirolla C; Bonfigli AR; Franceschi C; Marchegiani F; Offidani A
Int J Immunopathol Pharmacol; 2007; 20(4):731-6. PubMed ID: 18179745
[TBL] [Abstract][Full Text] [Related]
51. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist.
Vgontzas AN; Zoumakis E; Lin HM; Bixler EO; Trakada G; Chrousos GP
J Clin Endocrinol Metab; 2004 Sep; 89(9):4409-13. PubMed ID: 15356039
[TBL] [Abstract][Full Text] [Related]
52. Inflammation and type 2 diabetes.
Calle MC; Fernandez ML
Diabetes Metab; 2012 Jun; 38(3):183-91. PubMed ID: 22252015
[TBL] [Abstract][Full Text] [Related]
53. Effects of TNF-α blocking on experimental periodontitis and type 2 diabetes in obese diabetic Zucker rats.
Grauballe MB; Østergaard JA; Schou S; Flyvbjerg A; Holmstrup P
J Clin Periodontol; 2015 Sep; 42(9):807-816. PubMed ID: 26257165
[TBL] [Abstract][Full Text] [Related]
54. Effects of TNF-alpha antagonism on E-selectin in obese subjects with metabolic dysregulation.
Zanni MV; Stanley TL; Makimura H; Chen CY; Grinspoon SK
Clin Endocrinol (Oxf); 2010 Jul; 73(1):48-54. PubMed ID: 19878508
[TBL] [Abstract][Full Text] [Related]
55. Effects of etanercept in patients with the metabolic syndrome.
Bernstein LE; Berry J; Kim S; Canavan B; Grinspoon SK
Arch Intern Med; 2006 Apr; 166(8):902-8. PubMed ID: 16636217
[TBL] [Abstract][Full Text] [Related]
56. [Effect of wuhuang tangkangling on cytokine in patients with type 2 diabetes mellitus].
Hua ZQ; Chang YJ
Zhongguo Zhong Yao Za Zhi; 2013 Feb; 38(4):622-4. PubMed ID: 23713294
[TBL] [Abstract][Full Text] [Related]
57. [Preliminary exploration on effect of qilian decoction in intervention treatment of diabetes mellitus type 2 with insulin resistance and its influence on related inflammatory cytokines].
Gao SR; Bu JH; Zhu LZ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 Jul; 24(7):593-5. PubMed ID: 15307695
[TBL] [Abstract][Full Text] [Related]
58. Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
Larsen CM; Faulenbach M; Vaag A; Vølund A; Ehses JA; Seifert B; Mandrup-Poulsen T; Donath MY
N Engl J Med; 2007 Apr; 356(15):1517-26. PubMed ID: 17429083
[TBL] [Abstract][Full Text] [Related]
59. Fatigue symptoms relate to systemic inflammation in patients with type 2 diabetes.
Lasselin J; Layé S; Dexpert S; Aubert A; Gonzalez C; Gin H; Capuron L
Brain Behav Immun; 2012 Nov; 26(8):1211-9. PubMed ID: 22469909
[TBL] [Abstract][Full Text] [Related]
60. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2.
Sha BE; Valdez H; Gelman RS; Landay AL; Agosti J; Mitsuyasu R; Pollard RB; Mildvan D; Namkung A; Ogata-Arakaki DM; Fox L; Estep S; Erice A; Kilgo P; Walker RE; Bancroft L; Lederman MM
AIDS Res Hum Retroviruses; 2002 Jun; 18(9):661-5. PubMed ID: 12079562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
